11.96

2.29% -0.28

After Hours: 11.96

Dyne Therapeutics Inc (DYN)

Overview News Price History Option Chain Financials Why DYN Down? Discussions Forecast

Dyne Therapeutics Inc stock is traded at $11.96, with a volume of 1.13M. It is down -2.29% in the last 24 hours and up +2.05% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Previous Close:

$12.24

Open:

$12.02

24h Volume:

1.13M

Relative Volume:

0.49

Market Cap:

$1.36B

Revenue:

Net Income/Loss:

$-294.51M

P/E Ratio:

-3.3596

EPS:

-3.56

Net Cash Flow:

$-244.42M

1W Performance:

+2.31%

1M Performance:

+2.05%

6M Performance:

-60.93%

1Y Performance:

-61.67%

1-Day Range:

$11.51

$12.10

1-Week Range:

$11.51

$12.34

52-Week Range:

$6.36

$47.45

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name

Dyne Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(781) 786-8230

Address

1560 TRAPELO ROAD, WALTHAM

Employee

192

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

DYN's Discussions on Twitter

Compare DYN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DYN Dyne Therapeutics Inc	11.96	1.33B	0	-294.51M	-244.42M	-3.56
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-13-24	Initiated	Robert W. Baird	Outperform
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral
May-21-24	Reiterated	Chardan Capital Markets	Buy
Apr-30-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	H.C. Wainwright	Buy
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy
Feb-15-23	Initiated	Oppenheimer	Outperform
Jan-26-23	Initiated	Guggenheim	Buy
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Outperform
Oct-12-20	Initiated	JP Morgan	Overweight
Oct-12-20	Initiated	Jefferies	Buy
Oct-12-20	Initiated	Piper Sandler	Overweight
Oct-12-20	Initiated	Stifel	Buy

View All

Dyne Therapeutics Inc Stock (DYN) Latest News

May 30, 2025

Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Evercore ISI - Defense World

May 30, 2025

May 29, 2025

Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World

May 29, 2025

Dyne Therapeutics (DYN) Receives Outperform Rating as Confidence Grows | DYN Stock News - GuruFocus

May 29, 2025

May 27, 2025

Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com

May 27, 2025

May 25, 2025

Ameriprise Financial Inc. Increases Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World

May 25, 2025

May 24, 2025

Deutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World

May 24, 2025

May 22, 2025